Cancer Therapy with Nanoparticle-Medicated Intracellular Expression of Peptide CRM1-Inhibitor.Sui, M., Xiong, M., Li, Y., Zhou, Q., Shen, X., Jia, D., Gou, M., Sun, Q.
(2021) Int J Nanomedicine 16: 2833-2847
- PubMed: 33883894
- DOI: https://doi.org/10.2147/IJN.S266398
- Primary Citation of Related Structures:
6A38, 6A3A, 6A3B, 6A3C, 6A3E, 6KFT
- PubMed Abstract:
Peptides can be rationally designed as non-covalent inhibitors for molecularly targeted therapy. However, it remains challenging to efficiently deliver the peptides into the targeted cells, which often severely affects their therapeutic efficiency.
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, People's Republic of China.